HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén, Lisa LU
; Landberg, Göran
LU
; Stal, Olle
; Nordenskjold, Bo
; Fernö, Mårten
LU
and Bendahl, Pär-Ola
LU
(2008)
In Breast Cancer Research and Treatment
109(2).
p.351-357
- Abstract
- Background Overexpression of human epidermal growth factor receptor 2 (HER2) or amplification of its gene is a prognostic factor in primary breast cancer and a predictor for tamoxifen treatment efficacy in oestrogen receptor (ER) positive disease. In the present study we explored a defined cohort of breast cancer patients included in a randomised trial in order to assess prognostic and tamoxifen treatment information yielded by HER2 status.
Methods Premenopausal breast cancer patients with stage II tumours (n = 564) were included and allocated to 2 years of adjuvant tamoxifen treatment versus no adjuvant treatment. ER, progesterone receptor (PR) status and HER2 status was determined by immunohistochemistry using a tissue... (More) - Background Overexpression of human epidermal growth factor receptor 2 (HER2) or amplification of its gene is a prognostic factor in primary breast cancer and a predictor for tamoxifen treatment efficacy in oestrogen receptor (ER) positive disease. In the present study we explored a defined cohort of breast cancer patients included in a randomised trial in order to assess prognostic and tamoxifen treatment information yielded by HER2 status.
Methods Premenopausal breast cancer patients with stage II tumours (n = 564) were included and allocated to 2 years of adjuvant tamoxifen treatment versus no adjuvant treatment. ER, progesterone receptor (PR) status and HER2 status was determined by immunohistochemistry using a tissue microarray. HER2 amplification was analysed by fluorescent in situ hybridisation and tumours being amplified and/or HER2 3+ were considered HER2+. HER2 status was evaluable in 83% of the patients and 12.6% were HER2+. In untreated patients, HER2 was a negative prognostic factor in ER+ patients, HR 2.95; 95% CI: 1.61–5.38, p < 0.001, but not in ER- patients, HR 0.67; 95% CI: 0.28–1.61, p = 0.4, and a significant interaction between the two markers was found, p < 0.01. HER2 status was not related to tamoxifen treatment efficacy in ER+ patients (term of interaction p = 0.95). When stratifying for PR status, similar results were achieved.
Discussion HER2+ and ER+ breast cancer constituted a subgroup of tumours with poor prognosis in premenopausal breast cancer, whereas no treatment interaction was found between HER2 status and tamoxifen in ER+ tumours. The poor prognosis in HER2+ and ER+ patients may interfere with the interpretation of HER2 data in non-randomised trials of adjuvant tamoxifen. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/540653
- author
- Rydén, Lisa
LU
; Landberg, Göran
LU
; Stal, Olle
; Nordenskjold, Bo
; Fernö, Mårten
LU
and Bendahl, Pär-Ola
LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Breast Cancer Research and Treatment
- volume
- 109
- issue
- 2
- pages
- 351 - 357
- publisher
- Springer
- external identifiers
-
- wos:000255954200017
- scopus:43149123572
- pmid:17636399
- ISSN
- 1573-7217
- DOI
- 10.1007/s10549-007-9660-2
- language
- English
- LU publication?
- yes
- id
- f4ced8ec-70c2-49be-b2ad-edf1aac401ea (old id 540653)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17636399&dopt=Abstract
- date added to LUP
- 2016-04-01 14:52:28
- date last changed
- 2022-01-28 02:58:51
@article{f4ced8ec-70c2-49be-b2ad-edf1aac401ea,
abstract = {{Background Overexpression of human epidermal growth factor receptor 2 (HER2) or amplification of its gene is a prognostic factor in primary breast cancer and a predictor for tamoxifen treatment efficacy in oestrogen receptor (ER) positive disease. In the present study we explored a defined cohort of breast cancer patients included in a randomised trial in order to assess prognostic and tamoxifen treatment information yielded by HER2 status.<br/><br>
Methods Premenopausal breast cancer patients with stage II tumours (n = 564) were included and allocated to 2 years of adjuvant tamoxifen treatment versus no adjuvant treatment. ER, progesterone receptor (PR) status and HER2 status was determined by immunohistochemistry using a tissue microarray. HER2 amplification was analysed by fluorescent in situ hybridisation and tumours being amplified and/or HER2 3+ were considered HER2+. HER2 status was evaluable in 83% of the patients and 12.6% were HER2+. In untreated patients, HER2 was a negative prognostic factor in ER+ patients, HR 2.95; 95% CI: 1.61–5.38, p < 0.001, but not in ER- patients, HR 0.67; 95% CI: 0.28–1.61, p = 0.4, and a significant interaction between the two markers was found, p < 0.01. HER2 status was not related to tamoxifen treatment efficacy in ER+ patients (term of interaction p = 0.95). When stratifying for PR status, similar results were achieved.<br/><br>
Discussion HER2+ and ER+ breast cancer constituted a subgroup of tumours with poor prognosis in premenopausal breast cancer, whereas no treatment interaction was found between HER2 status and tamoxifen in ER+ tumours. The poor prognosis in HER2+ and ER+ patients may interfere with the interpretation of HER2 data in non-randomised trials of adjuvant tamoxifen.}},
author = {{Rydén, Lisa and Landberg, Göran and Stal, Olle and Nordenskjold, Bo and Fernö, Mårten and Bendahl, Pär-Ola}},
issn = {{1573-7217}},
language = {{eng}},
number = {{2}},
pages = {{351--357}},
publisher = {{Springer}},
series = {{Breast Cancer Research and Treatment}},
title = {{HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.}},
url = {{http://dx.doi.org/10.1007/s10549-007-9660-2}},
doi = {{10.1007/s10549-007-9660-2}},
volume = {{109}},
year = {{2008}},
}